REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
13.16
+0.18 (1.39%)
At close: Dec 5, 2025, 4:00 PM EST
13.16
0.00 (0.00%)
After-hours: Dec 5, 2025, 5:01 PM EST
REGENXBIO Employees
REGENXBIO had 353 employees as of December 31, 2024. The number of employees increased by 9 or 2.62% compared to the previous year.
Employees
353
Change (1Y)
9
Growth (1Y)
2.62%
Revenue / Employee
$456,992
Profits / Employee
-$504,008
Market Cap
666.20M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RGNX News
- 10 days ago - REGENXBIO to Participate in Upcoming Investor Conference - PRNewsWire
- 4 weeks ago - REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 5 weeks ago - REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program - PRNewsWire
- 5 weeks ago - REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights - PRNewsWire
- 7 weeks ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting - PRNewsWire
- 2 months ago - REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD - PRNewsWire